Sign in to download the Issue in PDF format.
1Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India
2Department of Ophthalmology, S.C.B Medical College, Cuttack, Odisha, India
S Dey
, R Sarkar, A Pradhan, P Padhan, D Maikap
Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.
Cite this article as: Dey S, Sarkar R, Pradhan A, Padhan P, Maikap D. Tofacitinib in Refractory Scleritis: A Case Series. Mediterr J Rheumatol 2023;34(3):367-71
Article Submitted: 24 Mar 2023; Revised Form: 16 Jul 2023; Article Accepted: 19 Jul 2023; Available Online: 28 Aug 2023
https://doi.org/10.31138/mjr.20230828.ti
This work is licensed under a Creative Commons Attribution 4.0 International License.
